P rotein ubiquitination is a post-translational modification that regulates both protein function and abundance 1 . A trio of enzymes, ubiquitin-activating enzyme (E1), E2, and ubiquitinligating enzyme (E3), work in series to conjugate ubiquitin to a lysine residue on a target protein through an isopeptide bond 2 . The modification has myriad cellular effects, and, as a consequence, mutations in components of the ubiquitination machinery are linked to human diseases, including cancer and neurodevelopmental and neurodegenerative disorders 3 . Mutations in ubiquitination enzymes are documented contributors to neurodevelopmental pathophysiology in intellectual disability (ID) and autism spectrum disorders 4 . A prototypical disorder involving an altered ubiquitination enzyme is X-linked intellectual disability (XLID) type Nascimento 5 , related to abnormalities in the UBE2A gene (gene ID 7319). The human locus for the UBE2A gene is at Xq24, and the transcript is ubiquitously expressed; the highest mRNA levels are in the heart, testis, and brain 6 . Individuals with this syndrome carry intragenic mutations (point mutations or small deletions) or larger Xq24 deletions encompassing the UBE2A gene 5, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Common clinical features include moderate to severe ID, prominent dysmorphic features, impaired speech, urogenital malformations, skin abnormalities, and epilepsy
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. A trio of enzymes, ubiquitin-activating enzyme (E1), E2, and ubiquitinligating enzyme (E3), work in series to conjugate ubiquitin to a lysine residue on a target protein through an isopeptide bond 2 . The modification has myriad cellular effects, and, as a consequence, mutations in components of the ubiquitination machinery are linked to human diseases, including cancer and neurodevelopmental and neurodegenerative disorders 3 . Mutations in ubiquitination enzymes are documented contributors to neurodevelopmental pathophysiology in intellectual disability (ID) and autism spectrum disorders 4 . A prototypical disorder involving an altered ubiquitination enzyme is X-linked intellectual disability (XLID) type Nascimento 5 , related to abnormalities in the UBE2A gene (gene ID 7319). The human locus for the UBE2A gene is at Xq24, and the transcript is ubiquitously expressed; the highest mRNA levels are in the heart, testis, and brain 6 . Individuals with this syndrome carry intragenic mutations (point mutations or small deletions) or larger Xq24 deletions encompassing the UBE2A gene 5, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Common clinical features include moderate to severe ID, prominent dysmorphic features, impaired speech, urogenital malformations, skin abnormalities, and epilepsy 10 . Larger deletions encompassing UBE2A and adjacent genes appear to result in severe forms of the clinical syndrome with a higher prevalence of white-matter changes, heart defects, and urogenital malformations than observed in patients with intragenic UBE2A pathogenic variants.
UBE2A shares 95% amino acid identity with UBE2B (gene ID 7320) at 5q31.1, but UBE2B variants are associated with only male infertility 20 . Molecular mechanisms linking mutations in UBE2A to neurodevelopmental disorders are still poorly understood. Emerging data implicate defective mobilization of the E3 Parkin as a source of neuronal vesicle trafficking and clearance of dysfunctional mitochondrial abnormalities, both of which are suspected to contribute to the neurodevelopmental phenotype in patients with UBE2A-deficiency syndrome 11 . Previously reported pathogenic mutations are distributed along the six exons of the UBE2A gene 5, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Limited functional and structural information on mutant forms of UBE2A limit current understanding of the contribution of specific UBE2A variants to the pathogenesis of ID.
We identified a novel missense mutation, c.277 C> G (p.Q93E) in UBE2A, in two brothers presenting with an atypical phenotype of only mild ID and impaired speech. We characterized the effects of this novel mutation on UBE2A function and structure to reveal the molecular mechanisms underlying the human disorder. We found that the Q93E mutation yields an enzyme with impaired ability to transfer ubiquitin to lysine, thereby inhibiting product formation. The defect is not rescued by the presence of an E3 ligase (RAD18) toward a specific UBE2A target, PCNA. Our results implicate Q93 of UBE2A in the deprotonation of an incoming lysine, a crucial step for ubiquitin transfer from an E2~ubiquitin conjugate to the substrate. Strikingly, the activity of the UBE2A Q93E mutant is partially recovered by increased pH, thus providing initial evidence of a potential reversion of a defective mutation in UBE2A related to XLID type Nascimento.
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identify the etiology of the condition. Recent whole-exome sequencing revealed that the affected individuals carry a missense variant in UBE2A exon 5 (chromosome X: 1187165 c.277 C> G). This variant had not previously been reported. Sanger sequencing confirmed the mutation in the probands and was used to determine familial segregation (Fig. 1b) . The mother and three unaffected daughters are heterozygous carriers of the UBE2A mutation ( Supplementary Fig. 1 ). All female carriers show extreme skewed X inactivation in peripheral blood (> 90%). The variant was therefore considered the cause of the phenotype. The mutation results in an amino acid change of glutamine to glutamate at position 93 near the active site of UBE2A. Position 93 is a glutamine in both UBE2A and UBE2B, but this residue is not highly conserved among E2s ( Supplementary Fig. 2 ).
The Q93E mutation impairs UBE2A activity. Given the proximity of Q93 to the catalytic cysteine, we tested whether the mutation might alter general UBE2A activity. Purified recombinant wild-type (WT) and Q93E-mutant UBE2A were assayed for their ability to generate polyubiquitin chains 21 . Each E2 was incubated with E1, ATP/Mg 2+ , and ubiquitin, in the absence of an E3 or a substrate. WT UBE2A generated high-molecular-weight products, as detected by western blotting against ubiquitin, but there was a marked lack of products generated by the mutant E2 (Fig. 1c) . To test whether the loss of activity was due to impaired conjugation of ubiquitin to the mutant E2 by E1, we compared assays in which the E2~ubiquitin (Ub) conjugate was visualized directly (Fig. 1d) . Both WT and Q93E-mutant UBE2A were robustly conjugated with ubiquitin, thus suggesting that the defect was in the second (transfer) step of product formation.
In the assay shown in Fig. 1c , products are generated when a lysine on an acceptor ubiquitin (Ub acceptor ) attacks the thioester of E2~Ub donor , and an aminolysis reaction ensues. To test whether the Q93E mutation might affect the intrinsic aminolysis activity of UBE2A, we performed lysine discharge assays. Activity toward the ε -amino group of free lysine reflects the ability of E2~Ub conjugates to transfer ubiquitin without complications associated with protein substrates 22, 23 . After the addition of free lysine to E2~Ub, WT UBE2A~Ub was depleted within ~10 min, whereas depletion of UBE2A Q93E~U b took longer than 30 min ( Fig. 1e and Supplementary  Fig. 3a) . Hence, UBE2A Q93E is compromised in aminolysis activity toward free lysine and lysine attached to ubiquitin. . The mother is a heterozygous carrier. c, Anti-ubiquitin western blot analysis of in vitro ubiquitination assays of WT UBE2A and Q93E-mutant enzymes, in the presence (+ ) or absence (-) of the reducing agent DTT. d, Thioester-bond formation, monitored by SDS-PAGE with nonreducing ((-) DTT) or reducing ((+ ) DTT) sample loading buffer. MW, molecular weight. e, Evaluation of the UBE2A~Ub conjugate's ability to transfer ubiquitin to free lysine, as visualized by SDS-PAGE in nonreducing conditions. Ub, ubiquitin; diUb, diubiquitin; Ub n , polyubiquitin chain; UBE2A~Ub, thioester conjugate of ubiquitin with UBE2A; asterisk, double concentration of UBE2A Q93E mutant in reaction.
Articles
NATURE CHEmICAl BIology
The activity of other UBE2A mutations previously reported to be involved in XLID type Nascimento, namely R7W, R11Q, and G23R 7, 11 , were compared. Each XLID mutant showed a detectable decrease in polyubiquitin-chain formation in vitro ( Supplementary Fig. 4a ), although the decreases were more modest than those observed for the Q93E mutant. Ubiquitin conjugation to the E2 active site was not impaired in these mutants ( Supplementary Fig. 4b ). These mutation sites are far from the E2 active site: R7 and R11 are in the putative E1/E3-binding surface, and G23 is on the 'back side' surface of UBE2A that binds the E3 enzyme RAD18 (ref. 21 ).
XLID Q93E mutation affects the UBE2A catalytic site. We determined crystal structures of WT and Q93E-mutant UBE2A at 1.85-and 2.20-Å resolution, respectively ( Fig. 2a and Supplementary  Table 1 ) and compared the structures. Superposition of the two structures revealed high similarity (r.m.s. deviation of 0.17 Å) and a typical E2 fold, featuring a four-stranded antiparallel β -sheet, four α -helices, and a short 3 10 helix 24 . The most notable difference is the loss of a hydrogen bond between the Q93 side chain and the backbone carbonyl of L89-the residue adjacent to active site C88 ( Fig. 2b and Supplementary Fig. 5 ).
We used NMR spectroscopy to gain more insight into the basis for the lower activity of UBE2A Q93E. Assignment of backbone resonances of UBE2A Q93E was performed with standard triple-resonance approaches; the backbone assignments for WT UBE2A were based on previously reported UBE2B NMR spectra (BMRB 17443). Overlay of the ( 1 H, 15 N)-HSQC spectra of WT and Q93E-mutant UBE2A indicated that the spectra are highly similar, and residues near the catalytic site (T69, V70, L89, W96, and A122) and the catalytic C88 (Fig. 2c-e) exhibit small chemical-shift perturbations (CSPs). In agreement with the loss of hydrogen-bonding between L89 and Q93 implied from the mutant crystal structure, the two largest CSPs are for L89 and C88, thus confirming that the Q93E mutation detectably alters the chemical environment of the catalytic residue.
XLID Q93E mutation preserves the UBE2A~Ub conformation. The orientation and interactions of ubiquitin within the E2 active site play a central role in its transfer to substrate 25 . In the structurally characterized E2~Ub conjugates, the conjugated ubiquitin is flexible and assumes a range of conformations relative to the E2 domain 26 . Binding of an E2~Ub to some RINGtype E3s promotes a 'closed' state of the conjugate, in which ubiquitin is positioned against the E2 helix α 2 (cross-over helix) (refs 26,27 ). The closed state has enhanced reactivity, presumably through positioning the thioester bond for nucleophilic attack by incoming lysine 28 . We investigated whether the ability 
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of UBE2A~Ub to adopt a closed conformation might be altered in the mutant, by monitoring the formation of an oxyester conjugate of the UBE2A C88S variant, which is more stable than the thioester conjugate 25 . (Fig. 3a,b) . We observed perturbations to residues on helix α 2 (residues D101, S103, I105, S111, L112, and L113) (Fig. 3b) , the E2 region that interacts with ubiquitin in the closed conformation 26 . (UBE2A Q93E -O~Ub) showed similar perturbations to those observed with UBE2A-O~Ub conjugate (Fig. 3c) .
A reciprocal setup allowed us to observe changes to the [ 15 N] ubiquitin spectra after oxyester conjugation ( Supplementary  Fig. 6a ). The CSPs were highly similar for both conjugates ( Fig. 3d and Supplementary Fig. 6a ). A crystal structure of the yeast homolog of UBE2A, Rad6~Ub, is in an open state; 29 therefore, to assess whether the UBE2A oxyester conjugates might adopt a closed state in solution, we built a molecular model of UBE2A~Ub, which was based on a Ubc13~Ub crystal structure (PDB 5AIU) 30 in a closed conformation (Fig. 3e ). In the model of UBE2A~Ub, the NMR-perturbed ubiquitin residues I44, K48, Q49, V70, and L71 are in the interface with E2 helix α 2 (refs 31, 32 ). Thus, the NMR results indicate that UBE2A-O~Ub visits closed conformations in 
Q93E
-O~Ub conjugates is in ubiquitin Gly76, the residue that forms the oxyester bond with UBE2A ( Supplementary Fig. 6a ). This difference indicates that the chemical environment of the oxyester bond (the mimic of the reactive bond of E2~Ub) is altered in the UBE2A Q93E -O~Ub conjugate. The human E2, UBE2D2 (UbcH5b), has arginine at the position homologous to UBE2A Q93. Substitution of R90 in UBE2D2 with glutamate (UBE2D2 R90E) generates a mutant with impaired polyubiquitination activity 33 . An interaction between the substituted glutamate residue in UBE2D2 R90E and R74 in the C-terminal tail of ubiquitin has been proposed to explain the loss of function. If a similar interaction is at play in UBE2A Q93E, we would predict a difference in the chemical shift of the ubiquitin R74 peak between UBE2A WT~U b and UBE2A Q93E~U b, but no such difference was observed ( Supplementary Fig. 6b ). Furthermore, the peak corresponding to E93 was not perturbed between the apo and conjugate form of the E2 ( Supplementary Fig. 6c ). Together, these observations do not support an interaction similar to the source of the activity defect in UBE2A Q93E~U b. Finally, given that an interaction between ubiquitin and the back sides of some E2 enzymes is critical for polyubiquitin-chain formation 21, 33, 34 , we tested whether the Q93E mutation might affect the UBE2A back-side interaction with ubiquitin. The ( 1 H, 15 N)-HSQC spectra of WT and Q93E-mutant UBE2A in the presence of a tenfold molar excess of ubiquitin were highly similar ( Supplementary  Fig. 7 ), thus confirming that the weak back-side interaction was not detectably impaired.
Overall, the data demonstrate that the activity defects of UBE2A Q93E are not due to altered conformation of either the apo or conjugate form. Instead, the evidence suggests a change in the chemical microenvironment of the active site.
UBE2A residue Q93 facilitates ubiquitin transfer. The ability to observe side chain NH 2 resonances for glutamine and asparagine side chains by NMR allowed us to follow the fate of the Q93 side chain during UBE2A C88S oxyester formation (Fig. 4a) . Although the Q93 backbone amide resonance is unperturbed after ubiquitin conjugation (Fig. 4a) , its side chain NH 2 resonances are considerably perturbed (Fig. 4a) . To further investigate the Q93 side chain, we generated the thioester in the NMR tube with WT UBE2A. The Q93 side chain resonances have different resonance positions in (uncharged) WT and C88S-mutant UBE2A, in agreement with the notion that Q93 senses the chemical environment of the active site (-SH versus -OH; Supplementary Fig. 8 ). In the first spectrum after ATP addition (collected for 80 min after ATP addition), we observed a substantial CSP in the C88 peak ( Supplementary Fig. 9a ) and the Q93 side chain peaks ( Fig. 4b ; red spectrum). At 5 h after ATP addition, a second set of Q93 side chain resonances that are further shifted appear ( Fig. 4b ; cyan spectrum). The observation of two sets of peaks indicates that the Q93 side chain exists in two slowly interconverting conformations at that point in the reaction. Importantly, neither of the Q93 resonances overlay with the original peak ( Fig. 4b ; black spectrum), so neither corresponds to discharged, unmodified UBE2A. In the same spectrum, there is a substantial loss of intensity for most peaks. A set of specific UBE2A residues exhibit an even larger decrease in peak intensity ( Supplementary Fig. 9a,b) , essentially the same residues that were perturbed in the UBE2A-O~Ub oxyester spectra ( Supplementary Fig. 9c and Fig. 3b ), thus indicating that the effect is linked to the formation of the thioester bond between UBE2A and ubiquitin. We propose that the Q93 side chain participates in a new interaction during the process. To test this hypothesis, we examined the effect of Q93 substitution with alanine on polyubiquitin-chain-assembly activity. As predicted, the Q93A substitution showed lower UBE2A activity than did WT UBE2A (Fig. 5a) Fig. 2 ).
The defective Q93E mutant is active in alkaline conditions. The Q93E mutant is more severely impaired than UBE2A Q93A in its polyubiquitination activity, thus suggesting that the presence of the carboxylate group of E93, as opposed to the loss of the amide group of Q93, is particularly detrimental to activity (Fig. 5a) . In assays performed under varying pH, the ability of UBE2A Q93E to assemble polyubiquitin chains was partially restored at pH 9 or above (Fig. 5b ).
An essential step in ubiquitin transfer via aminolysis is deprotonation of the incoming lysine, which acts as a nucleophile attacking the E2~Ub conjugate. Given the high pK a of lysine (approximately 10.5), residues near the E2 active site must create a microenvironment that lowers the effective pK a of the attacking lysine, thereby enabling formation of the isopeptide bond 35 . The calculated pK a value for a substrate lysine near the catalytic cysteine of the SUMOspecific E2 Ubc9 is almost 3 pH units lower than the pK a of free lysine 35 . The increase in UBE2A Q93E activity at high pH suggests that the mutant E2 lacks the ability to suppress the pK a of the incoming lysine, thereby slowing the rate of ubiquitin transfer to a lysine amino group. To test this hypothesis, we performed reactions with hydroxylamine (pK a ~ 6.0) 36 as the nucleophile, because it does not require deprotonation to act as a nucleophile at neutral pH. The initial rates of discharge with hydroxylamine, in contrast to reactions with free lysine (Fig. 1e) , were indistinguishable for WT and Q93E-mutant UBE2A (Fig. 5c and Supplementary Fig. 3b ). Both enzymes exhibited considerable activity, thus indicating that when deprotonation is not necessary, UBE2A Q93E is active. Together, the results strongly suggest that a primary effect of the UBE2A Q93E mutation is its inability to lower the pK a of the attacking lysine side chain.
To calculate the pK a value of lysine from an Ub acceptor molecule that is proximal to the catalytic site of UBE2A, we incorporated Fig. 10c,d ). e, Comparison between WT UBE2A and a mutant enzyme with a basic residue at position 93 (Q93R), through polyubiquitination assays at pH 8 (30 min). Ub, ubiquitin; diUb, diubiquitin; Ub n , polyubiquitin chain; UBE2A~Ub, thioester conjugate of ubiquitin with UBE2A.
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a ubiquitin molecule into our UBE2A~Ub donor model, which was based on the crystal structure of Ubc13~Ub presenting an acceptor ubiquitin near the thioester linkage (PDB 2GMI) 37 . With this model, multiconformational continuum electrostatics 38 predicted an increase in the lysine pK a from 9.3 in the WT complex to 13.7 in the UBE2A Q93E complex. The calculations support the notion that substitution of glutamate at position 93 leads to impaired lysine deprotonation caused by an increase in the pK a of the attacking lysine.
To gain insight into the activation of UBE2A Q93E at high pH, we measured the rate of diubiquitin formation by WT and Q93E-mutant enzymes at pH 8 and 9 ( Fig. 5d and Supplementary  Fig. 10 ). We conducted single-turnover assays in which the charging reactions were performed with lysine-free ubiquitin to hinder polyubiquitin formation ( Supplementary Fig. 10a) , and the discharge reactions were performed with an equimolar concentration of WT ubiquitin (after addition of EDTA to inhibit E1 enzyme). Diubiquitin formation was measured for both enzymes at the two pH conditions (Supplementary Fig. 10b ) and quantified, and the rates of product formation were determined from linearregression analysis (Supplementary Fig. 10c ). The rate of diubiquitin formation by UBE2A Q93E at pH 8 was approximately fourfold slower than that of WT UBE2A (0.013 ± 0.001 µ M/min versus 0.047 ± 0.008 µ M/min, respectively; Supplementary Fig. 10d ). Increasing the reaction pH from 8 to 9 led to a decrease in the gap between rates (0.041 ± 0.003 µ M/min for mutant versus 0.101 ± 0.006 µ M/min for WT UBE2A). The rate observed for UBE2A Q93E at pH 9 was quite similar to that of WT UBE2A at pH 8, thus corroborating the idea that the impairment caused by Q93E substitution can be overcome by increased pH.
To further explore this hypothesis, we substituted Q93 in UBE2A with arginine, the residue found in numerous E2s including UBE2D2. As predicted by our model, the Q93R mutation yielded greater UBE2A activity than the WT enzyme (Fig. 5e) . Thus, we conclude that the nature of the amino acid side chain of the position-93 residue in UBE2A directly contributes to enzyme activity via modulating lysine activation during ubiquitin transfer.
The UBE2A Q93E mutation diminishes monoubiquitination of PCNA. To assess the ubiquitin-transfer activity of UBE2A Q93E in the presence of an E3 and a substrate, we performed reactions containing either WT or Q93E-mutant UBE2A, the RING E3 RAD18, and the substrate PCNA. This pairing of E2 and E3 is known to transfer monoubiquitin to a specific lysine on PCNA 39 . Both forms of the E2 generate monoubiquitinated PCNA (Fig. 6 ), but both the rate and level of product formation were lower in UBE2A Q93E than the WT (half-life (t 1/2 ) of 22.8 min for UBE2A Q93E versus 6.9 min for WT). The results indicate that the aminolysis defect in UBE2A Q93E is not compensated by the E3 ligase RAD18, thus suggesting that the presence of mutant E2 may lead to decreased levels of ubiquitinated product. To assess whether a positively charged residue might facilitate lysine activation for ubiquitin transfer to substrate, we conducted the PCNA ubiquitination experiment with UBE2A Q93R (Fig. 6a) . The variant was highly active in this reaction, producing more product than WT UBE2A at a higher rate (t 1/2 of 2.9 min; Fig. 6b) . Together, the data show that the more active the E2 is intrinsically, the more product is generated in E3-dependent reactions.
Discussion
Mutations in the UBE2A gene are known to cause XLID 5, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Uncovering the molecular mechanisms underlying UBE2A-type ID can expand understanding of ID pathophysiology and clarify the fundamental catalytic mechanisms of this important class of enzymes. As central players in protein ubiquitination, E2s carry out two reactions: transthiolation, which conjugates ubiquitin to the E2 active site, and aminolysis, which transfers ubiquitin to an amino group on a substrate 23 . Here, we demonstrate that a novel pathogenic missense UBE2A mutation, Q93E, impairs the enzyme's ability to carry out aminolysis while its transthiolation activity is preserved. UBE2A Q93E is defective not only with ubiquitin serving as the nucleophile, thus inhibiting polyubiquitin-chain formation, but also with free lysine, thus indicating that the defect is in the aminolysis reaction itself. Furthermore, the mutant E2 is defective in its ability to monoubiquitinate PCNA in the presence of its cognate E3 ligase (RAD18), thereby indicating that the intrinsic defect cannot be fully overcome by an activating E3. These observations suggest that UBE2A Q93E generates its bona fide ubiquitinated products more slowly and at lower levels than WT UBE2A, even in the presence of cognate E3 ligases.
For lysine to act as a nucleophile, its ε -amino group must be deprotonated 35, 40 . Two mechanisms are proposed for lysine deprotonation by E2s: (i) direct abstraction of a proton by a proton acceptor and (ii) a decrease in the pK a of the incoming lysine, owing to the microenvironment near the E2 active site 35 . In the former case, D117 of UBE2D1 (ref. 41 ) and H94 of UBE2G2 (ref. 42 ) have been proposed to serve as proton acceptors for an incoming lysine. However, neither of the corresponding residues in UBE2A (S120 and Q93, respectively) can serve as proton acceptors, and indeed 
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none of the residues observed to be perturbed in UBE2A Q93E can receive a proton. Furthermore, the high similarity of ubiquitin resonances in UBE2A WT~U b and UBE2A Q93E~U b conjugates, other than for ubiquitin G76, do not support the existence of a proton acceptor in the ubiquitin moiety. Therefore, our work supports a mechanism in which lysine deprotonation is not carried out directly by a specific amino acid residue from UBE2A or Ub donor serving as proton acceptor.
Despite the conserved architecture of the active site and the position of the catalytic cysteine among E2s, the identity and location of residues that participate in catalysis differ, thus suggesting that the positioning and deprotonation of an incoming lysine may involve distinct sets of residues 43 . In the SUMO-specific E2 Ubc9, residues N85, Y87, and D127 near the active site cysteine provide a microenvironment that lowers the incoming lysine pK a , thereby enhancing deprotonation and nucleophilicity at physiological pH and helping to position the incoming lysine 35 . Although the NMR data indicate that substitution of glutamate for glutamine at position 93 perturbs the environment around the active site, the UBE2A residues corresponding to Ubc9 N85, Y87, and D127 (N80, Y82, and S120) exhibit no or very minor perturbations in the UBE2A Q93E spectra compared with the WT UBE2A spectra.
Our study identifies a previously unappreciated contribution of the Q93 side chain to the aminolysis reaction. Previous studies on UBE2B have indicated involvement of the Q93 residue in the formation of the thioester with ubiquitin 21 . In contrast, the defect in UBE2A Q93E is in discharge of the ubiquitin from the thioester and not in thioester formation. Residues at the Q93-equivalent position are not strictly conserved in the E2 family, although almost half of human E2s have arginine or lysine at this position, and only UBE2A and UBE2B have glutamine (Supplementary Fig. 2 ). Divergent effects of mutations at this E2 position have been reported. Substitutions with alanine inhibit formation of the E2~Ub conjugate in human UBE2C (UbcH10) 44 , restrict polyubiquitinchain formation by UBE2G2 (ref. 45 ), and have no apparent effect on the activity of UBE2D2 and UBE2K 33, 46 . In UBE2D2, UBE2K, and UBE2A, glutamate substitution at this position results in an E2 with impaired activity 33, 46 . The combined observations indicate that the 'Q93' position, which sits at the opening to the active site of E2s, may modulate both the thioester formation and discharge activities of an E2. A positively charged residue at this position appears to enhance activity, whereas substitution with a negatively charged glutamate impairs activity. Three human E2s, UBE2J2, UBE2U, and Ubc9, contain a negatively charged residue at this position, thereby suggesting that different residues are responsible for modulating the aminolysis reaction carried out by these E2s.
Studies conducted on cells from Ube2A-knockout mice or containing patient-derived UBE2A mutations (R7W, I87MfsX14, and Q128X) have common mitochondrial defects, which are suspected to be caused by defective polyubiquitination of mitochondrial proteins 11 . These studies have associated XLID mutations in UBE2A with disruptions in mitophagy 11 . The UBE2A R7W and R11Q mutations result in a loss of interaction with UBR4, a protein linked to lysosome-mediated degradation and autophagy 47 . The R11Q and G23R pathogenic mutations result in defects in polyubiquitin-chain assembly 21, 47 . Here, we show similar impairments in polyubiquitinchain assembly by the mutants R7W, R11Q, and G23R and even more pronounced impairments by the newly described Q93E mutation in UBE2A. Therefore, defects in polyubiquitin-chain formation and disruption of the mitophagy/autophagy processes appear to be a common feature related to different XLID UBE2A mutations.
Altogether, our data support a model in which glutamate at position 93 in UBE2A markedly decreases the enzyme´s ability to transfer ubiquitin from its active site to the ε -amino group of a lysine. The defect is caused by changes in the active site microenvironment that impair the decrease in the pK a of an incoming lysine, as is needed for its nucleophilicity. The results may have important implications for strategies to specifically inhibit UBE2A, which is recognized as a potential target for melanoma, breast, and ovarian cancer [48] [49] [50] . Moreover, our finding that increased pH can partially rescue UBE2A Q93E activity suggests the possibility of modulating the activity of the mutant enzyme with compounds that restore its ability to decrease the pK a of an incoming lysine.
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Methods
Patients. The two affected brothers were born to nonconsanguineous parents with no family history of neurodevelopmental disorders. Both patients were negative for fragile X syndrome and chromosome-microarray tests. The parents and the three female siblings are healthy.
Patient 1 was born at term after Caesarian section and weighed 4,160 g. A physical examination when the patient was 34 years old revealed a height of 1.81 m, a weight of 86 kg, hair whorls, thick eyebrows (without synophris), a large mouth, widely spaced nipples, normal genitalia, and shortened Achilles tendons. Temporal irritative focus was detected by routine EEG when the patient was 6 years old, but there were no convulsive or other epilepsy manifestations. He presented with mild ID, without substantially delayed motor milestones, but exhibited stuttering and difficulties in the articulation of words. He attends a special-education school, having achieved a level equivalent to the third or fourth grade of elementary schooling.
Patient 2 was born at term after Caesarian section and weighed 3,890 g. A physical examination when the patient was 32 years old revealed a height of 1.71 m, a weight of 55 kg, a moderate degree of frontal balding, hair whorls, thick eyebrows (without synophris), a large mouth, and normal genitalia. Similarly to his brother, he presented with mild ID; he did not present substantially delayed motor milestones but showed pronounced difficulties in the articulation of words. He also attends a special-education school and has achieved a level equivalent to the third or fourth grade of elementary schooling.
This study was approved by the ethics committee of the Institute of Biosciences (University of São Paulo, São Paulo, Brazil), and written informed consent was obtained from the patients' parents. The current work is in compliance with all relevant ethical regulations.
Whole-exome sequencing. DNA samples were prepared with the AmpliSeq Exome library, according to the manufacturer's specifications. The AmpliSeq libraries were single-end sequenced on an Ion Proton System at Beijing Genomics Institute (BGI, Beijing, China). The raw reads were aligned to the reference genome (GRCh37/hg19), with BWA 51 and preprocessed according to the GATK toolkit 52 . Filtering and prioritization of variants were conducted with VarSeq software (Golden Helix). The variants were filtered per population frequency (< 0.01), quality (phred quality ≥ 20, genotype quality ≥ 20), and read depth (10).
Sanger sequencing. Sanger sequencing was used to confirm the presence of the variants that were considered potentially pathogenic and to perform segregation studies (primer sequences available upon request).
X-inactivation analysis. X-inactivation, tested by determining the methylation status of the androgen receptor gene (AR), was evaluated as described previously 53 .
Cloning and mutagenesis. Sequences encoding the WT UBE2A gene and Q93E mutant were amplified by PCR from the patients' mothers' cDNA and index cDNA, respectively, and cloned into the pET28a vector (Novagen) via the NdeI and XhoI restriction sites. The human PCNA gene was also inserted into the pET28a vector through the same restriction sites. Human RAD18 was cloned between the restriction sites BamHI e XhoI of a modified version of pETSUMO (Invitrogen). Expression plasmids for human Uba1 and ubiquitin (both in pET3a) were donated by T. Sixma and C. Hill (Addgene plasmids #63571 and #61937, respectively). All point mutations in UBE2A (Q93E, Q93A, Q93R, C88S, C88S Q93E, R7W, R11Q, and G23R) were created with basic PCR-based site-directed mutagenesis and confirmed by Sanger sequencing.
Protein expression and purification. WT UBE2A (residues 1-152) and mutants (Q93E, Q93A, Q93R, C88S, C88S Q93E, R7W, R11Q, and G23R) were expressed from pET28a (Novagen) as an N-terminal hexahistidine-tag fusion. Rosetta II Escherichia coli cells (Novagen) were used to express the proteins in LB medium at 37 °C for 5 h at 200 r.p.m. The culture temperature was decreased to 18 °C for 1 h before induction with 0.2 mM IPTG, and cells were grown at 18 °C for 16 h, then harvested by centrifugation (5,000 g for 10 min at 4 °C). The cells were disrupted by sonication in lysis buffer (50 mM Tris, pH 7.5, 300 mM NaCl, 10% glycerol, 2 mM β -mercaptoethanol, and 1 mM phenylmethylsulfonyl fluoride) containing 0.2 mg/mL lysozyme and were centrifuged to remove cellular debris (40 000 g for 60 min at 4 °C). Proteins were first purified on a HisTrap column (GE Healthcare) preequilibrated with binding buffer containing 50 mM Tris, pH 7.5, 300 mM NaCl, and 2 mM β -mercaptoethanol, then were eluted with a linear gradient of the same buffer containing 500 mM imidazole, in an AKTA Purifier system (GE Healthcare). The hexahistidine tag was cleaved by thrombin protease, and the proteins were further purified with a Superdex 75 column (GE Healthcare) with buffer containing 50 mM Tris, pH 7.5, 300 mM NaCl, and 1 mM dithiothreitol. After being concentrated to 10 mg/ml, proteins were flash frozen in liquid nitrogen and stored at − 80 °C. Recombinant purified UBE2A proteins are shown in Supplementary Fig. 12 . Human Uba1, Ub, SUMO-RAD18, and PCNA were expressed and purified as previously described 21, 54, 55 .
Crystal-structure determination. Crystals were obtained by sitting-drop vapor diffusion at 18 °C by mixture of equal volumes of protein at 10 mg/mL and reservoir solution containing 50 mM disodium succinate, pH 7.0, and 12-14% PEG 3350. Harvested crystals were cryoprotected with 10% (vol/vol) ethylene glycol added to the mother liquor. Data were collected at 1.46 Å at beamline W01B-MX2 (LNLS) at 100 K, processed with XDS 56 , and merged and scaled with Aimless 57 . The structures were solved by molecular replacement with MolRep 57 . The human UBE2B protein (PDB 2YB6) 21 was used as a search model for WT UBE2A, whose structure was used as a search model for the Q93E mutant. The models were refined with Phenix (phenix.refine) 58 , and the quality of the final models was assessed with MolProbity. The crystallographic parameters and final refinement statistics are summarized in Supplementary Table 1 . Both final models contained 97.3% of residues in favored regions and 2.7% in allowed regions of the Ramachandran plot (no outliers).
NMR spectroscopy.
15 N-labeled WT and Q93E-mutant UBE2A proteins were produced in M9 minimal medium supplemented with 1 g/L N)-HSQC spectra were acquired on a 600-MHz spectrometer (Agilent Inova) equipped with a cryogenic probe. We used the backbone resonance assignment of apoubiquitin available in BMRB 4769.
In vitro ubiquitination assays. Ubiquitination assays were performed at 32 °C with 1 μ M human recombinant Uba1, 30 μ M human recombinant ubiquitin, and 20 μ M WT or Q93E-mutant UBE2A in ubiquitination buffer containing 50 mM Tris, pH 8.0, 50 mM NaCl, 50 mM KCl, 10 mM MgCl 2 , and 0.1 mM DTT. Reactions were started by the addition of 3 mM ATP and quenched with an equal volume of 2× SDS-PAGE buffer (reducing or nonreducing). Samples collected at specific time points were resolved by SDS-PAGE and were then western blotted with anti-ubiquitin (P4D1, Santa Cruz). In vitro ubiquitination assays at different pH values were conducted identically to those described above but with the following buffers: MES for pH 6, Tris for pH 7-9, and CAPS for pH 10. For intrinsicreactivity assays, WT and Q93E-mutant UBE2A were charged for 15 min at 32 °C in ubiquitination buffer before being mixed with 10 mM EDTA and 25 mM lysine or 5 mM hydroxylamine, and incubated at 32 °C. Samples were collected at several time points during the reaction, quenched in nonreducing SDS-PAGE buffer, and visualized by Coomassie staining. PCNA monoubiquitination was performed by mixture of 1 μ M Uba1, 30 μ M ubiquitin, 20 μ M WT or Q93E-mutant UBE2A, 5 μ M SUMO-RAD18, and 1 μ M PCNA in ubiquitination buffer supplemented with 2 μ M ZnCl 2 , with incubation at 32 °C in the presence of 3 mM ATP. The reactions were then subjected to anti-PCNA (P8825, Sigma) western blotting.
Single-turnover diubiquitin-formation assays. Diubiquitin-formation assays were conducted in two-step reactions. First, charging of UBE2A was achieved by mixture of 20 µ M of WT or Q93E-mutant UBE2A with 1 µ M E1, 30 µ M lysinefree ubiquitin, and 3 mM ATP in ubiquitination buffer, pH 8. After incubation for 15 min at 37 °C, the reactions were stopped by the addition of 25 mM EDTA and then diluted fourfold in ubiquitination buffer at pH 8 or 9 (both with 50 mM Tris-HCl), thus resulting in final concentrations of 0.25 µ M E1, 5 µ M UBE2A, and 7.5 µ M lysine-free ubiquitin. Diubiquitin formation was triggered by the addition of 7.5 µ M WT ubiquitin. Reactions were kept at 32 °C, and samples were collected at different time points and immediately quenched in reducing SDS-PAGE buffer. Results were evaluated by western blotting with anti-ubiquitin (P4D1, Santa Cruz), and quantification of the corresponding diubiquitin band was performed in ImageJ.
Molecular modeling. UBE2A was covalently bound to ubiquitin with the UBE2N~Ub structure (PDB 5AIU) 30 as the template. UBE2A was superposed with UBE2N, and the complex formed by UBE2A and ubiquitin was subjected to energy minimization with steepest descent followed by a simulated annealing protocol (SD/SA) to remove bad contacts, with the backbone atoms of UBE2A and ubiquitin fixed. We then created the thioester bond between the carboxyl 1 nature research | reporting summary The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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Population characteristics
The article includes investigation of two teenage boys with intellectual disability. The present study identified a mutation in the UBE2A gene, which explains their phenotype. Because it is an X-linked disorder and males are affected while females are asymptomatic carriers, their mother and sisters were also investigated for genetic counselling purposes. The characteristics of the patients are described on methods.
Recruitment
The family sought the Genetic Center at University of São Paulo for diagnosis of the two affected boys and genetic counselling. The parents agreed on participating in the study.
